Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Medtronic
McKinsey
Moodys
Johnson and Johnson

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for LDK378


Email this page to a colleague

« Back to Dashboard

What is the drug development status for LDK378?

LDK378 is an investigational drug.

There have been 31 clinical trials for LDK378. The most recent clinical trial was a Phase 2 trial, which was initiated on December 11th 2015.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Neoplasms. The leading clinical trial sponsors are Novartis Pharmaceuticals, National Cancer Institute (NCI), and Novartis.

There are two hundred and thirteen US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for LDK378
TitleSponsorPhase
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerNRG OncologyPhase 2
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 2
A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementYonsei UniversityPhase 2

See all LDK378 clinical trials

Clinical Trial Summary for LDK378

Top disease conditions for LDK378
Top clinical trial sponsors for LDK378

See all LDK378 clinical trials

US Patents for LDK378

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LDK378 ⤷  Sign up for a Free Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH) ⤷  Sign up for a Free Trial
LDK378 ⤷  Sign up for a Free Trial Polycyclic inhibitor of anaplastic lymphoma kinase XUANZHU PHARMA CO., LTD. (Jinan, Shandong Province, CN) ⤷  Sign up for a Free Trial
LDK378 ⤷  Sign up for a Free Trial .beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof Quadriga Biosciences, Inc. (Los Altos, CA) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LDK378

Drugname Country Document Number Estimated Expiration Related US Patent
LDK378 Australia AU2014348657 2033-11-13 ⤷  Sign up for a Free Trial
LDK378 Australia AU2017245411 2033-11-13 ⤷  Sign up for a Free Trial
LDK378 Australia AU2019246853 2033-11-13 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Medtronic
McKinsey
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.